Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The rs743572 common variant in the promoter of CYP17A1 is not associated with prostate cancer risk or circulating hormonal levels.

BJU international - 1 Feb 2008

Severi Gianluca, Hayes Vanessa M, Tesoriero Andrea A, Southey Melissa C, Hoang Hoa N, Padilla Emma J D, Morris Howard A, English Dallas R, Sutherland Robert L, Boyle Peter, Hopper John L, Giles Graham G

Abstract excerpt

OBJECTIVE: To use a large population-based case-control study to test the association between the common genetic variant rs743572 (-34 T to C), prostate cancer risk and circulating levels of several hormones. SUBJECTS AND METHODS: A previous meta-analysis concluded that reported associations between rs743572 in the promoter of CYP17A1 and prostate cancer risk might reflect publication bias, but a few recent...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Alleles
Share to Case-Control Studies
Share to Hormones
Share to Neoplasm Staging
Share to Promoter Regions, Genetic
Share to Prostatic Neoplasms
Share to Risk Factors
Share to Steroid 17-alpha-Hydroxylase

Source

Identifiers

PMID: 17986287
DOI: 10.1111/j.1464-410X.2007.07272.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The rs743572 common variant in the promoter of CYP17A1 is not associated with prostate cancer risk or circulating hormonal levels.PMID 17986287Read ↗

Quantitative assessment of the association between CYP17 rs743572 polymorphism and prostate cancer risk.Semantic proximity Read ↗

CYP17 gene polymorphisms and prostate cancer risk: a meta-analysis based on 38 independent studies.Semantic proximity Read ↗

CYP19A1 genetic variation in relation to prostate cancer risk and circulating sex hormone concentrations in men from the Breast and Prostate Cancer Cohort Consortium.Semantic proximity Read ↗

CYP17 genetic variation and risk of breast and prostate cancer from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3).Semantic proximity Read ↗

Polymorphism in the Androgen Biosynthesis Gene (CYP17), a Risk for Prostate Cancer: A Meta-Analysis.Semantic proximity Read ↗

Assessment of association between common variants at 17q12 and prostate cancer risk-evidence from Serbian population and meta--analysis.Semantic proximity Read ↗

Association of the CYP17 gene polymorphism with the risk of prostate cancer: a meta-analysis.Semantic proximity Read ↗

Polymorphisms in CYP17 and CYP3A4 and prostate cancer in men of African descent.Semantic proximity Read ↗

Cytochrome P450 3A gene variation, steroid hormone serum levels and prostate cancer--The Rotterdam Study.Semantic proximity Read ↗

CYP17 gene promoter allelic variant is not associated with prostate cancer.Semantic proximity Read ↗

No association of the 5' promoter region polymorphism of CYP17 gene with prostate cancer risk.Semantic proximity Read ↗

A novel polymorphism in the 17beta-hydroxysteroid dehydrogenase type 5 (aldo-keto reductase 1C3) gene is associated with lower serum testosterone levels in caucasian men.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.